Study S000757

PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm in Patients Treated With Semaglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, for Weight Reduction

ClinicalTrials.gov record

Registration

Registration: NCT07446998
Acronym: PLATEAU
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 239
Start: 2026-03-26
Primary completion: 2027-10
Lead sponsor: Veru Inc.
Conditions: Obesity & Overweight; Mobility Disability; HOMA-IR
Interventions: DRUG:Enobosarm; DRUG:Semaglutide (Wegovy) weekly injection
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:U1111-1343-2062

Registered primary outcomes

To determine the effect of enobosarm in combination with semaglutide on total body weight compared to semaglutide alone. [Day 476]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.